On June 22, WuXi XDC rose 3.25% in regular trading, trading at HKD 48.2/share, with turnover of HKD 175 million. The gain was driven by a combination of a broker recommendation and a new subsidiary order.

BOCOM International recently published a research report noting that the pharmaceutical industry performed steadily in the first half, recommending leading players with strong growth visibility and attractive valuations. WuXi XDC was listed as a key recommended target, alongside Asymchem and Pharmaron. The broker expects Hong Kong-listed sector leaders to maintain double-digit revenue and net profit growth.

Additionally, WuXi XDC's controlled subsidiary TOT BIOPHARM entered into a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, TOT BIOPHARM will deliver ten batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help deepen its technical know-how and enhance manufacturing capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)